Philips Healthcare posted second-quarter (end-June 30) revenue increases in its Diagnosis & Treatment division, which includes its medical imaging operations.
The segment posted revenues of 2.117 billion euros ($2.5 billion U.S.), up 10% from 1.919 billion euros ($2.266 billion) for the same period in 2020. The quarter saw the introduction of Philips' new Spectral CT 7500 system and a renewed partnership with radiation oncology firm Elekta to collaborate further on personal cancer care and treatment, the company said. Additionally, Philips' image-guided therapy, enterprise diagnostic informatics, diagnostic imaging, and ultrasound businesses all showed double-digit growth.
The Diagnosis & Treatment division posted income from operations of 262 million euros ($309.4 million) compared with 104 million euros ($122.8 million) for the same period the year before. Adjusted earnings before interest, taxes, and appreciation (EBITA) margin increased to 13.2%, compared with 8.7% in the second quarter of 2020.
"Looking ahead, while we continue to see uncertainty related to the impact of COVID-19 across the world and electronic component shortages, our financial outlook remains within our guided range," CEO Frans van Houten said in a July 26 statement released by the firm.
